Drug Trial Radar · NCT05610202
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Last checked: Nov 19, 2026Latest source record: Nov 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
137
Planned (sponsor's estimate)
Start
Nov 2022
Primary completion
Aug 2024
Study completion Aug 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the tolerability and preliminary efficacy of TQB3702 tablets in hematological tumor subjects.
Conditions
- Hematologic Malignancy
Interventions
TQB3702 tabletsDrug
TQB3702 tablets are selective BTK inhibitors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: Baseline up to 104 weeks
- Dose limited toxicity (DLT)Time frame: Baseline up to 104 weeks
- Recommended Phase II Dose (RP2D)Time frame: Baseline up to 104 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The Cancer Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.